Portal de Periódicos da CAPES

Identification of Haptoglobin as a Readout of rhGH Therapy in GH Deficiency

2019; Oxford University Press; Volume: 104; Issue: 11 Linguagem: Inglês

10.1210/jc.2019-00562

1945-7197

Marilisa De Feudis, Gillian E. Walker, Giulia Genoni, Marcello Manfredi, Emanuela Agosti, Mara Giordano, Marina Caputo, Luisa Di Trapani, Emílio Marengo, Gianluca Aimaretti, Nicoletta Filigheddu, Simonetta Bellone, Gianni Bona, Flavia Prodam,

Neuroblastoma Research and Treatments

Abstract Background GH deficiency (GHD) is characterized by a cluster of cardiovascular risk factors and subtle inflammation. We aimed to demonstrate, through a proteomic approach, molecules directly modulated by GHD and involved in the inflammatory state. Methods Ten children with isolated GHD were studied before and after 1 year of treatment with rhGH and compared with 14 matched controls. A two-dimensional electrophoresis plasma proteomics analysis was performed at baseline and after GH treatment to identify the top molecules modulated by GH. In vitro studies on human hepatoma (HepG2) cells were performed to validate the data. Results Twelve of 20 proteomic spots were predicted to be isoforms α and β of haptoglobin (Hp) and confirmed by liquid chromatography tandem mass spectrometry and Western immunoblot analyses. Hp levels were higher in patients with GHD than controls at baseline (P < 0.001) and were reduced following GH treatment (P < 0.01). In HepG2 cells, both GH and IGF-1 were able to downregulate IL-6–induced Hp secretion. Moreover, Hp secretion was restored in pegvisomant-treated HepG2 cells. Conclusions Hp is a molecule acting in the inflammatory state of GHD and a possible biomarker for GH treatment. Nevertheless, the contribution of other factors and the molecular pathways involved in the GH downregulation of Hp remain to be clearly defined.